Total Payments
$616,367
2024 Payments
$48,318
Companies
27
Transactions
542
Medicare Patients
3,167
Medicare Billing
$338,639
Payment Breakdown by Category
Other$468,056 (75.9%)
Consulting$87,858 (14.3%)
Travel$41,812 (6.8%)
Food & Beverage$11,813 (1.9%)
Research$6,620 (1.1%)
Education$208.45 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $463,856 | 173 | 75.3% |
| Consulting Fee | $87,858 | 37 | 14.3% |
| Travel and Lodging | $41,812 | 111 | 6.8% |
| Food and Beverage | $11,813 | 214 | 1.9% |
| Unspecified | $6,620 | 1 | 1.1% |
| Honoraria | $4,200 | 1 | 0.7% |
| Education | $208.45 | 5 | 0.0% |
Payments by Type
General
$609,747
541 transactions
Research
$6,620
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $267,827 | 237 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $99,826 | 93 | $0 (2024) |
| PFIZER INC. | $59,923 | 54 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $41,291 | 26 | $0 (2022) |
| Janssen Biotech, Inc. | $39,290 | 41 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $24,718 | 11 | $0 (2023) |
| Takeda Pharmaceuticals International, Inc. | $23,948 | 2 | $0 (2019) |
| Merck Sharp & Dohme LLC | $11,709 | 19 | $0 (2024) |
| Celgene Corporation | $10,177 | 18 | $0 (2022) |
| Takeda Pharmaceuticals America, Inc. | $9,906 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,318 | 36 | Janssen Biotech, Inc. ($24,208) |
| 2023 | $81,880 | 52 | AbbVie Inc. ($44,083) |
| 2022 | $86,034 | 69 | ABBVIE INC. ($42,779) |
| 2021 | $71,109 | 73 | AbbVie Inc. ($24,900) |
| 2020 | $28,504 | 26 | AbbVie Inc. ($14,377) |
| 2019 | $134,562 | 94 | AbbVie, Inc. ($41,248) |
| 2018 | $80,900 | 91 | AbbVie, Inc. ($23,434) |
| 2017 | $85,060 | 101 | AbbVie, Inc. ($52,946) |
All Payment Transactions
542 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $88.34 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $123.31 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $790.68 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $111.70 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $7.61 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $130.50 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $18.09 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $563.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $64.35 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $40.92 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Immunology | ||||||
| 10/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $60.76 | General |
| Category: IMMUNOLOGY | ||||||
| 10/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Immunology | ||||||
| 10/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $98.31 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug), REMICADE, STELARA | Food and Beverage | In-kind items and services | $33.01 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $6,620 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 657 | 786 | $334,270 | $77,388 |
| 2022 | 11 | 811 | 861 | $374,393 | $79,600 |
| 2021 | 12 | 869 | 1,026 | $390,871 | $97,858 |
| 2020 | 14 | 830 | 951 | $319,052 | $83,794 |
Total Patients
3,167
Total Services
3,624
Medicare Billing
$338,639
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 97 | 102 | $67,218 | $19,329 | 28.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 160 | 163 | $90,302 | $14,971 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 201 | $40,977 | $13,456 | 32.8% |
| 46221 | Removal of external hemorrhoids by rubber banding | Office | 2023 | 18 | 52 | $15,905 | $7,209 | 45.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 80 | 86 | $31,562 | $5,300 | 16.8% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 35 | 40 | $43,760 | $4,127 | 9.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 28 | 29 | $13,485 | $3,564 | 26.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 20 | 20 | $9,300 | $3,310 | 35.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 37 | 37 | $11,507 | $2,406 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $5,780 | $2,164 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 33 | $4,475 | $1,552 | 34.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 117 | 127 | $83,550 | $24,184 | 28.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 179 | 186 | $102,949 | $14,893 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 104 | $25,688 | $7,555 | 29.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 120 | 123 | $45,141 | $7,513 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 86 | 94 | $23,218 | $5,147 | 22.2% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 35 | 36 | $39,384 | $3,676 | 9.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $10,695 | $3,038 | 28.4% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 29 | 30 | $9,330 | $2,336 | 25.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 13 | 13 | $6,045 | $2,293 | 37.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $5,033 | $2,284 | 45.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 13 | $6,045 | $2,205 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 27 | 27 | $6,353 | $1,911 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 32 | $5,568 | $1,630 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 31 | 31 | $5,394 | $935.58 | 17.3% |
About Dr. Tauseef Ali, M.D
Dr. Tauseef Ali, M.D is a Gastroenterology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1417096041.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tauseef Ali, M.D has received a total of $616,367 in payments from pharmaceutical and medical device companies, with $48,318 received in 2024. These payments were reported across 542 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($463,856).
As a Medicare-enrolled provider, Ali has provided services to 3,167 Medicare beneficiaries, totaling 3,624 services with total Medicare billing of $338,639. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Oklahoma City, OK
- Active Since 02/06/2007
- Last Updated 10/22/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1417096041
Products in Payments
- STELARA (Biological) $116,244
- Humira (Biological) $74,982
- SKYRIZI (Biological) $53,861
- Entyvio (Biological) $52,271
- XELJANZ (Drug) $46,307
- RINVOQ (Biological) $40,153
- HUMIRA (Biological) $28,724
- ZEPOSIA (Drug) $26,595
- TREMFYA (Drug) $22,853
- ENTYVIO (Biological) $18,750
- REBYOTA (Biological) $6,530
- INFLECTRA (Biological) $5,301
- RENFLEXIS (Biological) $4,846
- VELSIPITY (Drug) $4,200
- Talicia (Drug) $2,805
- CYLTEZO (Drug) $1,650
- XIFAXAN (Drug) $164.74
- Trulance (Drug) $124.83
- SUCRAID (Drug) $98.19
- Hera W10 (Device) $50.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Oklahoma City
George Salem, Md, MD
Gastroenterology — Payments: $872,730
Gastroenterology $872,730
Pooja Singhal
Gastroenterology — Payments: $178,683
Gastroenterology $178,683
Matthew Mcbride, Md, MD
Gastroenterology — Payments: $83,407
Gastroenterology $83,407
Dr. Trushar Patel, M.d, M.D
Gastroenterology — Payments: $81,054
Gastroenterology $81,054
Dr. David Stokesberry, M.d, M.D
Gastroenterology — Payments: $41,079
Gastroenterology $41,079
Sanjay Sikka, M.d, M.D
Gastroenterology — Payments: $31,487
Gastroenterology $31,487